公开(公告)号：US20220009989A1

公开(公告)日：2022-01-13

申请号：US17281813

申请日：2019-10-04

申请人： Novo Nordisk A/S

发明人： Martin Werner Borchsenius Muenzel ,  Susanne Hostrup ,  Gro Klitgaard Povlsen ,  Mathias Norrman ,  Thomas Boerglum Kjeldsen ,  Claudia Ulrich Hjoerringgaard ,  Peter Madsen

IPC分类号： C07K14/62 ,  C07K14/485

摘要： The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.

公开(公告)号：US11649269B2

公开(公告)日：2023-05-16

申请号：US17281813

申请日：2019-10-04

申请人： Novo Nordisk A/S

发明人： Martin Werner Borchsenius Muenzel ,  Susanne Hostrup ,  Gro Klitgaard Povlsen ,  Mathias Norrman ,  Thomas Boerglum Kjeldsen ,  Claudia Ulrich Hjoerringgaard ,  Peter Madsen

IPC分类号： A61K38/00 ,  C07K14/62 ,  C07K14/485

CPC分类号： C07K14/62 ,  C07K14/485 ,  A61K38/00

摘要： The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.